Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;33(4):844-862.
doi: 10.1038/s41375-019-0388-x. Epub 2019 Jan 30.

Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)

Georg Maschmeyer  1 , Julien De Greef  2   3 , Sibylle C Mellinghoff  4   5 , Annamaria Nosari  6 , Anne Thiebaut-Bertrand  7 , Anne Bergeron  8 , Tomas Franquet  9 , Nicole M A Blijlevens  10 , Johan A Maertens  11   12 ; European Conference on Infections in Leukemia (ECIL)
Affiliations
Review

Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)

Georg Maschmeyer et al. Leukemia. 2019 Apr.

Abstract

A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists, infectious disease specialists, stem cell transplant experts, pulmonologists and radiologists have met within the framework of the European Conference on Infections in Leukemia (ECIL) to provide a critical state-of-the-art on infectious complications associated with immunotherapeutic and molecular targeted agents used in clinical routine. For brentuximab vedotin, blinatumomab, CTLA4- and PD-1/PD-L1-inhibitors as well as for ibrutinib, idelalisib, HDAC inhibitors, mTOR inhibitors, ruxolitinib, and venetoclax, a detailed review of data available until August 2018 has been conducted, and specific recommendations for prophylaxis, diagnostic and differential diagnostic procedures as well as for clinical management have been developed.

PubMed Disclaimer

Conflict of interest statement

GM accepted honoraria for lectures from Gilead, Pfizer, Boehringer Ingelheim, Celgene, Bristol-Myers Squibb, Merck-Serono, Novartis, honorarium for advice from Gilead and a travel grant from Bristol-Myers Squibb. JAM accepted grants, personal fees and nonfinancial support from MSD, Astellas, Pfizer and Gilead, personal fees and nonfinancial support from Basilea and F2G and personal fees from Scynexis. The other authors declare that they have no conflict of interest.

References

    1. Blincyto summary of product characteristics. https://www.ema.europa.eu/documents/product-information/blincyto-epar-pr.... Accessed 24 December 2018.
    1. Goebeler Maria-Elisabeth, Bargou Ralf. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leukemia & Lymphoma. 2016;57(5):1021–1032. - PubMed
    1. Wang Kemeng, Wei Guoqing, Liu Delong. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental Hematology & Oncology. 2012;1(1):36. - PMC - PubMed
    1. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., Noppeney R., Viardot A., Hess G., Schuler M., Einsele H., Brandl C., Wolf A., Kirchinger P., Klappers P., Schmidt M., Riethmuller G., Reinhardt C., Baeuerle P. A., Kufer P. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody. Science. 2008;321(5891):974–977. - PubMed
    1. Nägele V, Kratzer A, Zugmaier G, Holland C, Hijazi Y, Topp MS, et al. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. Exp Hematol Oncol. 2017;6:14. - PMC - PubMed

MeSH terms